Identification of three tumor antigens and immune subtypes for mRNA vaccine development in diffuse glioma

• Published in: Theranostics 2021-01, Vol.11 (20), p.9775-9790
• Main Authors: Zhou, Quanwei, Yan, Xuejun, Zhu, Hecheng, Xin, Zhaoqi, Zhao, Jin, Shen, Wenyue, Yin, Wen, Guo, Youwei, Xu, Hongjuan, Zhao, Ming, Liu, Weidong, Jiang, Xingjun, Ren, Caiping
• Format: Article
• Language: English
• Subjects: Antigens; Antigens, Neoplasm - immunology; Biomarkers, Tumor - genetics; Brain cancer; Brain Neoplasms - pathology; Cancer therapies; Cancer Vaccines - immunology; Chemotherapy; China; Clinical outcomes; Collagen Type I - genetics; Databases, Genetic; Datasets; Gene expression; Gene Expression - genetics; Gene Expression Profiling - methods; Gene Expression Regulation, Neoplastic - genetics; Genomes; Genomics; Glioma; Glioma - genetics; Glioma - immunology; Glioma - therapy; Humans; Immunotherapy; Intracellular Signaling Peptides and Proteins - genetics; Medical prognosis; Melanoma; mRNA vaccines; mRNA Vaccines - genetics; mRNA Vaccines - pharmacology; Mutation; Patients; Prognosis; Research Paper; RNA, Messenger - genetics; Survival Analysis; Transcriptome - genetics; Tumor Microenvironment - immunology; Tumors; Vascular Endothelial Growth Factor Receptor-2 - genetics
• ISSN: 1838-7640; 1838-7640
• DOI: 10.7150/thno.61677

Diffuse glioma patients have high mortality and recurrence despite multimodal therapies. This study aims to identify the potential tumor antigens for mRNA vaccines and subtypes suitable for the immunotherapy of patients with diffuse glioma. Gene expression profiles and corresponding clinical information were obtained from the Chinese Glioma Genome Atlas (CGGA) and the Cancer Genome Atlas (TCGA) databases. Genetic alterations were extracted from cBioPortal. Differential gene analysis, survival analysis, correlation analysis, consensus clustering analysis, and immune cell infiltration analysis were conducted based on the various databases. Finally, the hub genes, the modules related to tumor antigens, and the immune subtypes were identified using WGCNA method. Three over-expressed, amplified, and mutated tumor antigens, including KDR, COL1A2, and SAMD9, were associated with clinical outcomes. The expression of the three genes had a positive correlation with the abundance of antigen-presenting cells (APCs) and APC marker expression. Subsequently, three immune subtypes (Ims1, Ims2, and Ims3) were distinguished in the TCGA cohort, which exhibited distinct molecular, cellular, and clinical characteristics consistent with the CGGA cohort. Diffuse gliomas with subtype Ims1 were more malignant with immunosuppressive phenotypes and more associated with poor prognosis than the other two subtypes. The three antigens and the immune checkpoints were differentially expressed among the three immune subtypes. Finally, functional enrichment analysis of the genes related to tumor antigens and immune subtypes suggested that they are enriched in many immune-associated processes. KDR, COL1A2, and SAMD9 are potential antigens for developing mRNA vaccines against diffuse glioma. The results suggest that immunotherapy targeting these three antigens is more suitable for patients with subtype Ims1. This study provides insights into immunotherapy for diffuse glioma.